Sequence: rrrqrrkkr
| Experiment Id | EXP002416 |
|---|---|
| Paper | Cell-Penetrating Peptides and Peptide Nucleic Acid-Coupled MRI Contrast Agents: Evaluation of Cellul |
| Peptide | D-Tat57-49 / D-Tatinv |
| Delivery Success Class | no |
| In Vivo Flag | no |
| Uptake Confirmed | yes |
| Label Confidence | high |
| In Vitro Functional Effect | no |
| Endosomal Escape Evidence | no |
| Peptide Concentration | 2.5 µM (PNA-containing CA cell labeling; saturation >2.5 µM) |
| Rna Concentration | 2.5 µM PNA-containing conjugate |
| Mixing Ratio | covalent 1:1 peptide:PNA conjugate |
| Formulation Format | Covalent CPP-PNA-MRI/fluorescent contrast-agent conjugate |
| Formulation Components | Gd-DOTA + FITC + nonsense PNA + AEEA spacer + D-Tat57-49 |
| Size Nm | |
| Zeta Mv | |
| Model Scope | in_vitro |
| Model Type | in vitro |
| Cell Lines Or Primary Cells | DsRed2-expressing CCL-11 fibrosarcoma cells; parent CCL-11 cells |
| Animal Model | |
| Administration Route | |
| Output Type | Cellular uptake/MRI contrast enhancement; negative-control target binding |
| Output Value | MR contrast enhancement at 2.5 µM; failed to bind the synthetic DsRed target in cell-free assay |
| Output Units | |
| Output Notes | Control PNA conjugate showed similar cellular uptake/distribution to antisense CA; no functional RNA effect demonstrated. |
| Toxicity Notes | Dose increase above 2.5 µM accompanied by increased toxicity; no conjugate-related toxicity at working/in vivo conditions reported. |
| Curation Notes |